An Individual Patient-Level Meta-Analysis of Ischemic Versus Nonischemic Cardiomyopathy and Trajectory of Decongestion in Patients With Acute Decompensated Heart Failure

• Published in: The American journal of cardiology 2023-08, Vol.200, p.32-39
• Main Authors: Akhtar, Khawaja H., Maqsood, Muhammad Haisum, Ansari, Saad Ali, Siddiqi, Tariq Jamal, Arshad, Muhammad Sameer, Greene, Stephen J, Butler, Javed, Khan, Muhammad Shahzeb
• Format: Article
• Language: English
• Subjects: Brain natriuretic peptide; Cardiomyopathies - complications; Cardiomyopathies - therapy; Cardiomyopathy; Clinical outcomes; Clinical trials; Congestive heart failure; Creatinine; Diuretics; Dopamine; Dyspnea; Heart failure; Heart Failure - complications; Heart Failure - therapy; Hospitalization; Humans; Ischemia; Meta-analysis; Mortality; Myocardial Ischemia - complications; Patients; Respiration; Self assessment; Stroke Volume; Trends; Ultrafiltration; Ventricle; Ventricular Function, Left; Well being
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2023.04.043

Data are limited regarding the impact of ischemic cardiomyopathy (ICM) or non-ICM (NICM) on the trajectory of in-hospital decongestion among patients with acute decompensated heart failure (ADHF). Therefore, we aimed to assess the course of decongestion among patients admitted for ADHF by history of ICM and NICM. Patients included in the DOSE (Diuretic strategies in patients with acute decompensated heart failure), ROSE (ROSE acute heart failure randomized trial), and Ultrafiltration in decompensated heart failure with cardiorenal syndrome (CARRESS-HF) trials of patients with ADHF were categorized into ICM and NICM based on history. Among 762 patients included in our meta-analysis, 433 (56.8%) had a history of ICM. Patients with ICM were older (70.8 vs 63.9 years; p ≤0.001) and had higher rates of co-morbidities. After covariate adjustment, there was no significant differences between NICM and ICM regarding net fluid loss (4,952 vs 4,384 ml, p = 0.81) or mean change in serum N-terminal pro-brain natriuretic peptide (−2,162 vs −1,809 pg/ml, p = 0.092). Mean change in weight showed modest improvement in favor of patients with NICM, but this did not meet statistical significance (−8.24 vs −7.70 pounds, p = 0.068). After adjustment, there was no significant difference in the risk of 60-day composite all-cause mortality or hospitalization for HF among those with ICM versus NICM. Among patients with left ventricular ejection fraction 40%, NICM was associated with decreased scoring on global visual analog scale at 72 hours (+15.7 vs +21.2, p = 0.049). In conclusion, more than half of the patients admitted for ADHF had ICM. History of ICM was not independently associated with a difference in course of decongestion, self-assessment of well-being and dyspnea, or short-term clinical outcomes.